Assessing Perceptions of ML Explanations by Medical Oncologists

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT06699615
Status
Enrolling By Invitation

Conditions

  • Oncology

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Once time de-identified Qualtrics survey — OTHER
    Once time de-identified Qualtrics survey

Study Details

The objective of this proposal is to conduct a vignette-based survey among practicing oncology clinicians who treat non-small cell lung cancer to assess the trustworthiness of explainable predictions from a neurosymbolic AI vs. State-of-the-art post-hoc explanatory algorithms, using simulated patient data.

Key Dates

Start date
Dec 2, 2024
Status verified
Apr 2026
Primary completion
Apr 15, 2028
Completion
Apr 15, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: One time de-identified Qualtrics Survey

Primary Outcome Measure

Determine whether neurosymbolic AI explainability methods improve the trustworthiness of explanations from a prognostic model, relative to post-hoc explainers. [ Time Frame: 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19083-

Find similar trials in Philadelphia, PA

By research site
University of Pennsylvania· Philadelphia, PA

Related Studies